The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.

PubWeight™: 0.84‹?›

🔗 View Article (PMC 4574692)

Published in BMC Infect Dis on September 17, 2015

Authors

Kimberly M Thompson1, Radboud J Duintjer Tebbens2

Author Affiliations

1: Kid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL, 32832, USA. kimt@kidrisk.org.
2: Kid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL, 32832, USA. rdt@kidrisk.org.

Articles cited by this

Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet (2007) 3.73

New strategies for the elimination of polio from India. Science (2006) 3.27

Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet (2010) 3.13

Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1992) 3.07

Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis (2009) 2.05

Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science (2014) 2.00

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet (2014) 1.96

Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog (2012) 1.50

Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria. BMC Med (2014) 1.35

Expert review on poliovirus immunity and transmission. Risk Anal (2012) 1.18

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal (2013) 1.16

Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis (2015) 1.14

Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis (2014) 1.10

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal (2013) 1.10

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis (2014) 1.07

Successes and shortcomings of polio eradication: a transmission modeling analysis. Am J Epidemiol (2013) 1.06

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal (2013) 1.05

Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. J Infect Dis (1995) 1.04

Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis (2014) 1.03

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. BMC Infect Dis (2015) 1.03

Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. J Infect Dis (2014) 1.01

The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis (2014) 1.01

Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis (2014) 1.01

Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal (2012) 0.97

An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis (2015) 0.96

Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal (2013) 0.90

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. PLoS One (2015) 0.88

Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine (2015) 0.85

Quantifying the impact of expanded age group campaigns for polio eradication. PLoS One (2014) 0.83